Evidence map›Paper›PMID 28206960›Full record

ArticleOncotarget2017

An autocrine/paracrine circuit of growth differentiation factor (GDF) 15 has a role for maintenance of breast cancer stem-like cells.

Asako Sasahara, Kana Tominaga, Tatsunori Nishimura, Masao Yano, Etsuko Kiyokawa, Miki Noguchi, Masakuni Noguchi, Hajime Kanauchi, Toshihisa Ogawa, Hiroshi Minato and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Asako SasaharaDivision of Molecular Therapy, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Kana TominagaDivision of Molecular Therapy, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Tatsunori NishimuraDivision of Cancer Cell Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Masao YanoDepartment of Surgery, Minamimachida Hospital, Machida, Tokyo, Japan.
Etsuko KiyokawaDepartment of Oncologic Pathology, Kanazawa Medical University, Ishikawa, Japan.
Miki NoguchiDepartment of General and Digestive Surgery, Kanazawa Medical University, Ishikawa, Japan.
Masakuni NoguchiDepartment of General and Digestive Surgery, Kanazawa Medical University, Ishikawa, Japan.
Hajime KanauchiDepartment of Breast and Endocrine Surgery, Showa General Hospital, Kodaira, Tokyo, Japan.
Toshihisa OgawaDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Hiroshi MinatoDepartment of Pathology and Laboratory Medicine, Kanazawa Medical University, Ishikawa, Japan.
Keiichiro TadaDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Yasuyuki SetoDepartment of Gastrointestinal Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Arinobu TojoDivision of Molecular Therapy, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Noriko GotohDivision of Molecular Therapy, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Kanazawa Medical University · JPThe University of Tokyo · JPKanazawa University · JPTokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells are thought to be responsible for tumor growth, recurrence, and resistance to conventional cancer therapy. However, it is still unclear how they are maintained in tumor tissues. Here, we show that the growth differentiation factor 15 (GDF15), a member of the TGFβ family, may maintain cancer stem-like cells in breast cancer tissues by inducing its own expression in an autocrine/paracrine manner. We found that GDF15, but not TGFβ, increased tumor sphere formation in several breast cancer cell lines and patient-derived primary breast cancer cells. As expected, TGFβ strongly stimulated the phosphorylation of Smad2. GDF15 also stimulated the phosphorylation of Smad2, but the GDF15-induced tumor sphere forming efficiency was not significantly affected by treatment with SB431542, an inhibitor of the TGFβ signaling. Although TGFβ transiently activated ERK1/2, GDF15 induced prolonged activation of ERK1/2. Treatment with U0126, an inhibitor of the MEK-ERK1/2 signaling, greatly inhibited the GDF15-induced tumor sphere formation. Moreover, cytokine array experiments revealed that GDF15, but not TGFβ, is able to induce its own expression; furthermore, it appears to form an autocrine/paracrine circuit to continuously produce GDF15. In addition, we found heterogeneous expression levels of GDF15 among cancer cells and in human breast cancer tissues using immunohistochemistry. This may reflect a heterogeneous cancer cell population, including cancer stem-like cells and other cancer cells. Our findings suggest that GDF15 induces tumor sphere formation through GDF15-ERK1/2-GDF15 circuits, leading to maintenance of GDF15high cancer stem-like cells. Targeting GDF15 to break these circuits should contribute to the eradication of tumors.

Indexed as

Autocrine CommunicationBreast NeoplasmsCell Line, TumorCell ProliferationFemaleGrowth Differentiation Factor 15HumansMAP Kinase Signaling SystemMCF-7 CellsNeoplastic Stem CellsParacrine CommunicationGDF15 protein, humanGrowth Differentiation Factor 15breast cancercancer stem cellsERKTGFbetatumor spheres

Identifiers

PMID28206960
PMCPMC5421895
OpenAlexW2588974700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.